• Nicotine Signaling Drives CKD Progression via Oxidative Stre

  2026-05-07

  Jain and Jaimes (2013) provide a mechanistic review linking nicotine signaling to the progression of chronic kidney disease (CKD) in smokers. Their synthesis of clinical and experimental data underscores the roles of non-neuronal nicotinic acetylcholine receptors, oxidative stress, and fibrotic pathways, offering targets for research on intervention and disease modification.

• U 46619 (SKU B6890): Reliable Agonist for Platelet & Vascula

  2026-05-07

  This article explores five real-world scenarios in which U 46619 (11,9 epoxymethano-prostaglandin H2, SKU B6890) provides reproducible, data-driven solutions for platelet and vascular assays. Designed for biomedical researchers and lab technicians, the discussion highlights protocol optimization, data interpretation, and vendor selection, positioning APExBIO’s U 46619 as a robust tool for cardiovascular and renal research.

• Zoledronic Acid in ECM-Driven Oncology: Beyond Apoptosis Ass

  2026-05-06

  Explore how Zoledronic Acid, a nitrogen-containing bisphosphonate, enables advanced extracellular matrix (ECM) research in oncology. This article uniquely integrates mitochondrial NAD+ insights and practical assay optimization for cancer and bone disease studies.

• Lipid Peroxidation (MDA) Assay Kit: Precision in Oxidative S

  2026-05-06

  Harness the dual-mode sensitivity of the Lipid Peroxidation (MDA) Assay Kit to accurately quantify malondialdehyde in challenging biological matrices. Discover tailored workflows and troubleshooting strategies that empower bench scientists to decode oxidative stress mechanisms and drug resistance in disease models.

• Isradipine (Dynacirc): Elevating Calcium Channel Blockade in

  2026-05-05

  This thought-leadership article explores the mechanistic depth, experimental rigor, and strategic value of Isradipine (Dynacirc) as a selective L-type calcium channel antagonist. Bridging foundational pharmacology and translational opportunity, the piece empowers researchers to advance hypertension, neuroprotection, and neurodegenerative disease studies—while addressing the evolving limitations of classic channel-blocker paradigms. Insights from seminal v-Agatoxin-IVA literature and leading content assets are integrated to provide a next-generation framework for calcium signaling research.

• Optimizing Storage for LNP-Formulated Self-Replicating RNA V

  2026-05-05

  This study systematically evaluated storage conditions for lipid nanoparticle (LNP)-formulated self-replicating RNA (repRNA) vaccines, identifying protocols that maintain vaccine stability and in vivo potency for at least 30 days. The findings inform best practices for preserving polyadenylated mRNA-LNP formulations and provide a foundation for further applications in mRNA vaccine development.

• In Vivo CAR-T-mimicking Cells via Magnetic Bispecific Nano-a

  2026-05-04

  This study introduces a magnetic bispecific nano-antibody (M-BiNanoAb) strategy for generating CAR-T-mimicking cells in vivo and directing their migration into solid tumors via external magnetic fields. The approach demonstrates enhanced tumor infiltration and antitumor activity, offering a new path for solid tumor immunotherapy.

• Applied Uses of Recombinant Human EGF in Cell Migration Assa

  2026-05-04

  Recombinant human EGF is a gold-standard tool for driving cell proliferation and migration, with validated consistency across oncology and regenerative workflows. This article showcases optimized protocols, troubleshooting strategies, and experimental insights—empowering researchers to maximize reproducibility and biological relevance when leveraging APExBIO’s EGF in advanced cell-based assays.

• RBMS1 Loss Enables PD-L1 Blockade in Triple-Negative Breast

  2026-05-03

  This study identifies the RNA-binding protein RBMS1 as a crucial regulator of PD-L1 stability in triple-negative breast cancer (TNBC). Loss of RBMS1 enhances anti-tumor immunity by promoting the degradation of PD-L1, thereby improving the efficacy of immune checkpoint therapies. These findings reveal a promising therapeutic strategy for improving immunotherapy responses in immune-cold TNBC.

• Synergistic CDK4/6 and BET Inhibition Suppresses Pancreatic

  2026-05-02

  Gu et al. (2025) demonstrate that combined inhibition of CDK4/6 and BET proteins synergistically suppresses pancreatic ductal adenocarcinoma (PDAC) growth and reverses EMT by regulating the GSK3β-mediated Wnt/β-catenin pathway. These findings highlight the importance of targeting convergent oncogenic signaling networks for improved therapeutic outcomes in PDAC.

• Renal Blood Flow Effects of Norepinephrine in Septic Rats

  2026-05-02

  This study elucidates how K+ channel blockade alters renal blood flow responses to norepinephrine and phenylephrine in a rat sepsis model. The findings highlight the complex interplay between adrenergic signaling and vascular potassium channels, providing critical insights for experimental designs in cardiomyopathy research and sepsis-induced organ dysfunction.

• Immune Signatures from Epigenetic Inhibitors in Melanoma The

  2026-05-01

  Anichini et al. conducted a systematic comparison of epigenetic drugs in melanoma cell lines, revealing that DNMT inhibition by guadecitabine uniquely upregulates immune-related gene signatures. These findings guide the rational design of combinatorial immunotherapy strategies and suggest that immune modulation by epigenetic agents is highly context- and target-dependent.

• Bradykinin (BA5201): Technical Guidance for Vasodilator Stud

  2026-04-30

  Bradykinin (SKU BA5201) addresses the need for a reliable, high-purity endothelium-dependent vasodilator in cardiovascular, pain, and inflammation research workflows. It is best suited for acute-phase assays focused on vascular permeability modulation, smooth muscle contraction, and related signaling pathways, but is not recommended for diagnostic or clinical therapeutic applications.

• AG-221 (Enasidenib): Mechanism, Evidence & AML Research Util

  2026-04-30

  AG-221 (Enasidenib) is a selective inhibitor of mutant IDH2, clinically validated for reducing 2-hydroxyglutarate and reversing leukemogenic epigenetic changes in AML. Its robust in vivo and clinical data have set new standards in acute myeloid leukemia research targeting IDH2 mutations.

• Phenytoin in Sodium Channel Modulation: Experimental Insight

  2026-04-29

  Phenytoin (5,5-diphenylimidazolidine-2,4-dione) from APExBIO enables precise sodium channel modulation research and advanced electrophysiological workflows. This expert guide translates recent reference breakthroughs into actionable protocols, troubleshooting insights, and comparative perspectives for neurological disease models.

406 records 16/28 page Previous Next First page 上5页 1617181920 下5页 Last page